Brief: Xvivo Perfusion Q4 adjusted EBITDA drops to SEK 6.7 mln
Feb 8 (Reuters) - Xvivo Perfusion Ab XVIVO.ST :
* Q4 sales 38.4 million Swedish crowns ($4.32 million)
versus 32.7 million crowns year ago
* Q4 adjusted EBITDA 6.7 million crowns versus 7.2 million
crowns year ago
Source text for Eikon: ID:nWkr6pqCXT
Further company coverage: XVIVO.ST
($1 = 8.8803 Swedish crowns)
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength